Abstract:OBJECTIVE: To identify long-term outcomes and safety of transplantation of autologous peripheral blood stem cells (PBSC) for treating dilated cardiomyopathy. METHODS: A total of 38 cases with dilated cardiomyopathy received treatment at the Department of Cardiology, Guangdong General Hospital of Chinese People's Armed Police Forces, were selected, including 26 males and 12 females, aged 42-72 years, mean aged 56 years. Based on given standard therapy, 38 patients divided randomly into the transplantation group (n=20) and the control group (n=18). Patients in the transplantation group were received recombinant human granulocyte colony-stimulating factor (rhG-CSF) 300 ug/d once per day for 5 days to mobilize stem cells. At day 6, PBSC were collected with blood-cells separator and were transplanted through intracoroary way. The routine medication was performed in the control group. Blood routine test, hepatic function, renal function, glucose, triglyeride (TG), cholesterol, low density cholesterol (C-LDL), high density cholest-erol (C-HDL), uric acid (UA), creatine kinase (CK), isoenzyme of creatine kinase (CK-MB) and high sensitive C-reactive protein (hsCRP) were measured before and at months 6 and 12 after transplantation. All patients also received ultrasonic echocardiography, ECG Holter monitor and six-minute-walk test before and at 12 and 24 months after the procedure. Survival rate and incidence rate of heart incidents were compared. The study end-point was death from any cause. RESULTS: All patients received a 12-24 month follow-up with mean (18±6) months. One patient in the transplantation group received mitral valve replacement. One patient of the transplantation group and 2 of the control group died due to refractory heart failure. The blood routine test and biochemical indicators of the transplantation group had no significant differences among 6 months and 12 months after transplantation compared with control and pre-transplantation (P > 0.05). Six-minute-walking distance in the transplantation group significantly increased at 12 months after transplantation than pre-transplantation level, which was also higher than that of control patients (P < 0.05). The left ventricular ejection fraction (LVEF) was increased (P < 0.01). The left ventricular diastolic diameter (LVDd) decreased significantly in the transplantation group (P < 0.01). In the control group, improvement in LVEF and LVDd were observed, but there was no significant difference (P > 0.05). After 24 months of follow-up, the above-mentioned indexes had not improved in the transplantation group without significant differences. No malignant arrhythmias and severe side effects could be observed around transplantation and during 24 months follow-up. Survival was similar between the two groups during 24 months follow. CONCLUSION: Transplantation of mobilized autologous PBSC might be a safe and effective method for the treatment of dilated cardiomyopathy, which may improve the ventricular systolic function in a short-term, however, the long-term effects still uncertain.

Pulmonary Vascular Disease Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial Hypertension

Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients with Idiopathic Pulmonary Arterial Hypertension: a Pilot Randomized Controlled Trial.

Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: Open-label pilot study

Autologous Endothelial Progenitor Cells Transplantation for the Therapy of Primary Pulmonary Hypertension

Interruption of CD40 Pathway Improves Efficacy of Transplanted Endothelial Progenitor Cells in Monocrotaline Induced Pulmonary Arterial Hypertension.

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Intravenous infusion of autologous endothelial progenitor cells in treatment of primary pulmonary hypertension

Autologous Transplantation of Peripheral Blood Stem Cell in Treatment of Critical Limb Ischemia

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study.

Combined Hypoxia Inducible Factor-1Α and Homogeneous Endothelial Progenitor Cell Therapy Attenuates Shunt Flow–induced Pulmonary Arterial Hypertension in Rabbits

Transcatheter Arterial Infusion of Autologous CD133(+) Cells for Diabetic Peripheral Artery Disease.

[A Prospective, Randomized, Controlled Trial of Autologous Mesenchymal Stem Cells Transplantation for Dilated Cardiomyopathy].

Transplantation of Mobilized Peripheral Blood Mononuclear Cells for Peripheral Arterial Occlusive Disease of the Lower Extremity

Adipose-derived stromal cell autologous transplantation ameliorates pulmonary arterial hypertension induced by shunt flow in rat models.

Transplantation of endothelial progenitor cells from human peripheral blood improves limb ischemia

Autologous bone marrow mononuclear cell transplantation improves vascular endothelial function in patients with myocardial infarction and left ventricular dysfunction

Feasibility of Hypoxia Inducible Factor Gene Transfer in Endothelial Progenitor Cell for Vascular Regeneration

Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy:A 24-month follow-up in 38 cases

Autologous transplantation of peripheral blood mononuclear cells for lower limb ischemia in 27 cases

Cardiopulmonary Exercise Testing Combined with Haemodynamics for the Prediction of Outcome in Idiopathic Pulmonary Arterial Hypertension